1. Home
  2. MNSB vs ADCT Comparison

MNSB vs ADCT Comparison

Compare MNSB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$25.02

Market Cap

164.1M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.17

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
ADCT
Founded
2003
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.1M
136.1M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
MNSB
ADCT
Price
$25.02
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
20.4K
1.5M
Earning Date
04-20-2026
05-04-2026
Dividend Yield
1.68%
N/A
EPS Growth
210.00
30.86
EPS
1.05
N/A
Revenue
$135,615,000.00
$81,357,000.00
Revenue This Year
$1.50
N/A
Revenue Next Year
$3.77
$66.49
P/E Ratio
$23.50
N/A
Revenue Growth
N/A
14.85
52 Week Low
$17.86
$0.78
52 Week High
$25.87
$4.98

Technical Indicators

Market Signals
Indicator
MNSB
ADCT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MNSB
ADCT

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: